Recite me link

Q1. How many patients have been treated with biologics or biosimilar products in the last 12 months for the following conditions:
· Rheumatoid Arthritis
· Psoriatic Arthritis
· Ankylosing Spondylitis
· Non-Radiographic Axial Spondyloarthritis
Q2. Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 12 months with the following drugs.
· Abatacept [Orencia]
· Adalimumab [Amgevita]
· Adalimumab [Humira]
· Adalimumab [Hyrimoz]
· Adalimumab [Imraldi]
· Apremilast [Otezla]
· Baricitinib [Olumiant]
· Certolizumab [Cimzia]
· Etanercept [Benepali]
· Etanercept [Enbrel]
· Etanercept [Erelzi]
· Golimumab [Simponi]
· Infliximab [Flixabi]
· Infliximab [Inflectra]
· Infliximab [Remicade]
· Infliximab [Remsima]
· Ixekizumab [Taltz]
· Rituximab [MabThera]
· Rituximab [Rixathon]
· Rituximab [Truxima]
· Sarilumab [Kevzara]
· Secukinumab [Cosentyx]
· Tocilizumab [Ro Actemra]
· Tofacitinib [Xeljanz]
· Upadacitinib [Rinvoq]
· Ustekinumab [Stelara]

Download response Biologic and biosimilar product prescribing in Rheumatology. 211020